Production Approval for Mobocerinib

Release date: 2024-07-10 14:40:59     Recommended: 374

Mobocerinib is a kinase inhibitor suitable for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. FDA approved tests have detected that the disease progresses during or after platinum chemotherapy. Based on the overall response rate and response duration, the indication was approved under accelerated approval. The continued approval of this indication may depend on the validation and description of clinical benefits in confirmatory trials.